Literature DB >> 23159910

Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion through targeting laminin-332 in head and neck squamous cell carcinoma.

Takashi Kinoshita1, Toyoyuki Hanazawa, Nijiro Nohata, Naoko Kikkawa, Hideki Enokida, Hirofumi Yoshino, Takeshi Yamasaki, Hideo Hidaka, Masayuki Nakagawa, Yoshitaka Okamoto, Naohiko Seki.   

Abstract

Recent our microRNA (miRNA) expression signature revealed that expression of microRNA-218 (miR-218) was reduced in cancer tissues, suggesting a candidate of tumor suppressor in head and neck squamous cell carcinoma (HNSCC). The aim of this study was to investigate the functional significance of miR-218 and its mediated moleculer pathways in HNSCC. Restoration of miR-218 in cancer cells led to significant inhibition of cell migration and invasion activities in HNSCC cell lines (FaDu and SAS). Genome-wide gene expression analysis of miR-218 transfectants and in silico database analysis showed that focal adhesion pathway was a promising candidate of miR-218 target pathways. The laminins are an important and biologically active part of the basal lamina, the function of that are various such as influencing cell differentiation, migration and adhesion as well as proliferation and cell survival. Interestingly, all components of laminin-332 (LAMA3, LAMB3 and LAMC2) are listed on the candidate genes in focal adhesion pathway. Furthermore, we focused on LAMB3 which has a miR-218 target site and gene expression studies and luciferase reporter assays showed that LAMB3 was directly regulated by miR-218. Silencing study of LAMB3 demonstrated significant inhibition of cell migration and invasion. In clinical specimens with HNSCC, the expression levels of laminin-332 were significantly upregulated in cancer tissues compared to adjacent non-cancerous tissues. Our analysis data showed that tumor suppressive miR-218 contributes to cancer cell migration and invasion through regulating focal adhesion pathway, especially laminin-332. Tumor suppressive miRNA-mediated novel cancer pathways provide new insights into the potential mechanisms of HNSCC oncogenesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23159910      PMCID: PMC3717800          DOI: 10.18632/oncotarget.709

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


INTRODUCTION

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide and approximately 650,000 new cases occur and 350,000 patients dying from HNSCC annually [1]. Despite of considerable advances in multimodality therapy including surgery, radiation therapy, and chemotherapy, the overall survival rate for patients with this type of cancer is among the lowest of all major cancer types and has not improved during recent decades [2]. Local tumor recurrence and distant metastasis after conventional therapy appear to be major contributing factors for restricted survival of HNSCC patients [2]. Therefore, understanding the molecular metastatic pathways underlying HNSCC would help to improve diagnosis, approaches to therapy, and prevention of the disease. The discovery of non-coding RNA in human genome is a topic in post genome sequencing era [3]. The reconstructing of the genome-wide study, including non-coding RNA is necessary for cancer research at present. microRNAs (miRNAs) are most characterized among non-coding RNAs. miRNAs are a class of small non-coding RNA molecules consisting of 19–22 nucleotides that play important roles in a variety of biological processes, including development, differentiation, apoptosis and cell proliferation [4]. A growing body of evidence indicated that miRNAs also contributed to the initiation and development of various types of cancers [5, 6]. Many human cancers have aberrant expression of miRNAs, which can function either as tumor suppressors or oncogenes [6]. miRNAs are unique in their ability to regulate many protein-coding genes. Bioinformatics predictions indicate that miRNAs regulate more than 30% of the protein coding genes in human genome [4]. In cancer pathways, normal regulatory mechanisms are disrupted by altered expression of tumor suppressive or oncogenic miRNAs. We previously identified tumor suppressive miRNAs based on miRNA expression signatures of various types of cancer, such as hypopharyngeal, maxillary sinus, esophageal, and lung SCCs, and renal cell carcinoma and bladder cancer [7-13]. We hypothesize that normal regulatory miRNA-mRNA molecular mechanisms are disrupted by aberrant expression of tumor suppressive or oncogenic miRNAs in cancer cells. Therefore, we have sequentially identified tumor suppressive miRNAs regulated novel cancer pathways [7, 8, 14-20]. According to our HNSCC miRNA expression signatures, microRNA-218 (miR-218) was significantly reduced in cancer tissues [7, 8]. The downregulation of miR-218 was also reported in several cancers and its targeting cancer-related genes were identified [21-26]. The aim of the study was to investigate the functional significance of miR-218 and identify its regulating molecular pathways in HNSCC cells. Genome-wide gene expression analysis of miR-218 transfectant and in silico database analysis showed that focal adhesion pathway was a promising candidate of miR-218 target pathway. The laminins are an important and biologically active part of the basal lamina, influencing cell differentiation, migration and adhesion as well as proliferation and cell survival. Interestingly, all components of laminin-332 (LAMA3, LAMB3 and LAMC2) are listed on the candidate genes in focal adhesion pathway. Furthermore, we focused on LAMB3 which has a miR-218 target site and gene expression studies and luciferase reporter assays showed that LAMB3 was directly regulated by miR-218. We also investigated functional significance of LAMB3 in HNSCC and its regulated novel molecular pathways. Tumor suppressive miR-218-mediated novel cancer pathways provide new insights into the potential mechanisms of HNSCC oncogenesis and metastasis.

RESULTS

Effects of miR-218 transfection on proliferation, migration and invasion in HNSCC cells, FaDu and SAS

The expression levels of miR-218 in HNSCC cells (FaDu and SAS) were significantly downregulated compared with those in normal epithelial tissues (Figure 1A). This is why we used these cell lines to investigate functional analysis of miR-218 in this study. To investigate the tumor suppressive roles of miR-218, we conducted gain-of-function analysis using mature miRNA transient transfection.
Figure 1

Effects of miR-218 transfection on HNSCC cell lines, FaDu and SAS

(A)Real-time RT-PCR showed that expression levels of miR-218 was significantly lower in both cell lines, FaDu and SAS than in normal epithelial specimens. (B)Suppression of FaDu and SAS cell proliferation after transfection (72h) with miR-218 (10nM) was determined by XTT assay. (C) Suppression of FaDu and SAS cell migration activity after transfection (72h) with miR-218 (10nM) was determined by migration assay. (D) Suppression of FaDu and SAS cell invasion activity after transfection (72h) with miR-218 (10nM) was determined by Matrigel invasion assay. *p < 0.0167.

Effects of miR-218 transfection on HNSCC cell lines, FaDu and SAS

(A)Real-time RT-PCR showed that expression levels of miR-218 was significantly lower in both cell lines, FaDu and SAS than in normal epithelial specimens. (B)Suppression of FaDu and SAS cell proliferation after transfection (72h) with miR-218 (10nM) was determined by XTT assay. (C) Suppression of FaDu and SAS cell migration activity after transfection (72h) with miR-218 (10nM) was determined by migration assay. (D) Suppression of FaDu and SAS cell invasion activity after transfection (72h) with miR-218 (10nM) was determined by Matrigel invasion assay. *p < 0.0167. The XTT assay showed that the cell proliferation in miR-218 transfectants was reduced to approximately 85% of mock in FaDu and SAS (Figure 1B). The migration assay revealed that the number of migrated cells was significantly decreased in miR-218 transfectants compared with mock and miR-control transfectants (% of migrated cells relative to mock; FaDu, 3.9 ± 2.3, p < 0.0167; SAS, 11.7 ± 4.5, p < 0.0167; Figure 1C). The Matrigel invasion assay also showed significant decrease in the number of invaded cells in miR-218 transfectants (% of invaded cells relative to mock; FaDu, 3.1 ± 3.0, p < 0.0167; SAS, 17.1 ± 9.7, p < 0.0167; Figure 1D).

Identification of molecular pathways regulated by miR-218 in HNSCC

To find the target genes of miR-218 in HNSCC cells, we performed gene expression profiling using miR-218-transfected FaDu and SAS in comparison with the miR-control transfectants. When compared with the expression of miR-control transfectants, 525 genes were downregulated (log2 ratio < -0.5) in FaDu transfected with miR-218 and 831 genes in SAS (Supplementary table 1 and 2). Entries from the microarray data were approved by the Gene Expression Omnibus (GEO), and were assigned GEO accession numbers GSE37119. These genes were assigned to Kyoto Encyclopedia of Genes and Genomes (KEGG) annotations using singular enrichment analysis of GeneCodis [27, 28] and significantly enriched annotations in FaDu and SAS were listed (Table 1 and Table 2).
Table 1

Significantly enriched annotations regulated by miR-218 in FaDu

Number of Genesp ValueAnnotations
182.34E-08Focal adhesion
161.07E-11Systemic lupus erythematosus
151.51E-03Pathways in cancer
132.82E-04Regulation of actin cytoskeleton
101.97E-03Protein processing in endoplasmic reticulum
102.87E-02MAPK signaling pathway
91.70E-02Endocytosis
81.94E-03Amoebiasis
89.35E-03Hepatitis C
81.36E-02Wnt signaling pathway
83.36E-02Chemokine signaling pathway
73.25E-04Mineral absorption
73.24E-03Small cell lung cancer
71.44E-02Leukocyte transendothelial migration
61.46E-02ECM-receptor interaction
64.70E-02Toxoplasmosis
52.52E-02Adipocytokine signaling pathway
52.52E-02Long-term potentiation
52.54E-02Bacterial invasion of epithelial cells
52.89E-02Arrhythmogenic right ventricular cardiomyopathy
49.16E-03Thyroid cancer
42.54E-02Bladder cancer
44.08E-02Endometrial cancer
44.18E-02Non-small cell lung cancer
34.02E-02beta-Alanine metabolism
24.92E-02Valine, leucine and isoleucine biosynthesis
Table 2

Significantly enriched annotations regulated by miR-218 in SAS

Number of Genesp ValueAnnotations
212.05E-04Pathways in cancer
171.45E-04Focal adhesion
154.58E-04Endocytosis
142.79E-03Regulation of actin cytoskeleton
138.44E-04Protein processing in endoplasmic reticulum
111.14E-04ECM-receptor interaction
104.30E-03Lysosome
104.37E-02Chemokine signaling pathway
94.89E-03Amoebiasis
81.22E-04Bladder cancer
82.53E-03Pancreatic cancer
86.78E-03Apoptosis
83.94E-02Glutamatergic synapse
84.36E-02Tight junction
77.05E-03Adipocytokine signaling pathway
72.18E-02Small cell lung cancer
67.05E-03Lysine degradation
68.15E-03Mineral absorption
62.82E-02p53 signaling pathway
63.33E-02PPAR signaling pathway
63.38E-02Adherens junction
53.95E-02Non-small cell lung cancer
53.95E-02Vibrio cholerae infection
42.18E-02beta-Alanine metabolism
We focused on the focal adhesion pathway because this pathway can be implicated in cancer cell migration and invasion and can be a promising candidate of miR-218 target pathway. The genes that were annotated as focal adhesion pathway were then analyzed using in silico target prediction databases (miRWalk and TargetScan), generating a list of candidate target genes of miR-218 (Table 3). Interestingly, all three subunits of laminin-332 (LAMA3, LAMB3 and LAMC2) are all listed on these candidates. Therefore, we focused on laminin-332 as the target of miR-218 and further studied.
Table 3

Candidate target genes of miR-218 in the focal adhesion pathway

Gene symbolLog2 ratio (miR-218/miR-control)Putative miR-218 target site
FaDuSASAveragemiR WalkTarget Scan
CAV2−1.97−1.73−1.85++
PPP1CB−1.98−1.65−1.82++
LAMC2−1.51−0.96−1.24
ACTN1−1.13−1.27−1.20++
THBS2−0.60−1.61−1.11
LAMB3−1.25−0.90−1.08++
CAV1−1.20−0.95−1.08
EGFR−0.85−1.19−1.02++
VEGFC−0.90−1.03−0.97
PPP1CC−0.87−0.97−0.92++
COL5A20.93−2.66−0.87
CCND2−1.06−0.62−0.84+
VASP−0.82−0.72−0.77
CAV3−0.87−0.66−0.77++
THBS1−0.66−0.86−0.76++
COL4A2−0.72−0.58−0.65
ACTN4−0.69−0.57−0.63++
ITGA3−0.69−0.53−0.61
CCND3−0.76−0.37−0.57++
SHC1−0.64−0.45−0.55++
ITGB4−0.61−0.43−0.52+
PXN−0.67−0.33−0.50++
LAMC1−0.59−0.35−0.47++
VEGFA−0.19−0.63−0.41
ERBB2−0.06−0.62−0.34
LAMA3−0.760.08−0.34
FN1−0.11−0.54−0.33+
MAPK1−0.55−0.09−0.32
FLNB−0.630.30−0.17

Expression levels of miR-218 and laminin-332 in HNSCC clinical specimens

We performed qRT-PCR to compare the expression levels of miR-218, LAMA3, LAMB3 and LAMC2 in clinical HNSCC specimens. Clinical information for the 35 patients is shown in Table 4. The expression level of miR-218 was significantly downregulated in tumor tissues compared with adjacent normal tissues (p = 0.039; Figure 2A), whereas LAMA3, LAMB3 and LAMC2 were upregulated in tumor tissues (P = 0.018, p = 0.0029 and p = 0.0009, respectively; Figure 2B - 2D). Interestingly, LAMA3 and LAMC2 expression was significantly inversely correlated with miR-218 expression (r = −0.30, p = 0.014; and r = −0.35, p = 0.0040, respectively; Figure 2E and 2G). Although the expression of LAMB3 tended to inversely correlate with that of miR-218, statistical significance was not observed (r = −0.22, p = 0.064; Figure 2F).
Table 4

Clinical features for 35 patients with HNSCC

No.AgeSexSiteTNMStageDifferentiaion
168Mhypopharynx4a00IVAmoderately
273Mhypopharynx310IIIpoorly
366Mhypopharynx22c0IVAmoderately
468Mhypopharynx22b0IVApoorly
565Mhypopharynx12b0IVAmoderately
671Mhypopharynx22b0IVApoorly
764Fhypopharynx4a00IVAwell
864Mhypopharynx200IImoderately
955Mhypopharynx32b0IVAmoderately
1061Fhypopharynx4a2c0IVApoorly
1166Mhypopharynx4a2c0IVAwell
1258Fhypopharynx4a2c0IVAmoderately
1352Mhypopharynx4a11IVCmoderately
1474Mhypopharynx4a2c0IVApoorly
1564Mhypopharynx200IImoderately
1645Mhypopharynx4a2c0IVAmoderately
1764Fhypopharynx4a10IVApoorly
1879Mhypopharynx22c0IVAmoderately
1969Mhypopharynx22b0IVApoorly
2061Mhypopharynx300IIImoderately
2177Mgingiva200IImoderately
2265Moral floor4a10IVAmoderately
2363Foral floor22b0IVAmoderately
2468Mtongue200IImoderate
2566Mtongue200IImoderate
2676Ftongue100Iwell
2769Mtongue100Iwell
2873Ftongue100Iwell
2967Mtongue4a2c0IVAmoderately
3036Ftongue310IIImoderately
3167Mtongue300IIImoderately
3251Mtongue100Iwell
3370Mtongue4a00IVAmoderately
3471Mtongue100Iwell
3560Ftongue22b0IVAwell
Figure 2

The expression levels of miR-218 and laminin-332 in HNSCC clinical specimens

The expression levels of miR-218 (A), LAMA3 (B), LAMB3 (C) and LAMC2 (D) in tumor tissues and adjacent normal epithelium tissues of 35 HNSCC patients were determined by qRT-PCR. RNU48 and GUSB were used as internal controls. The correlated expression of miR-218 and laminin-332 was determined in HNSCC specimens. The correlation coefficient indicates that miR-218 expression was highly correlated with that of laminin-332, LAMA3 (E), LAMB3 (F) and LAMC2 (G).

The expression levels of miR-218 and laminin-332 in HNSCC clinical specimens

The expression levels of miR-218 (A), LAMA3 (B), LAMB3 (C) and LAMC2 (D) in tumor tissues and adjacent normal epithelium tissues of 35 HNSCC patients were determined by qRT-PCR. RNU48 and GUSB were used as internal controls. The correlated expression of miR-218 and laminin-332 was determined in HNSCC specimens. The correlation coefficient indicates that miR-218 expression was highly correlated with that of laminin-332, LAMA3 (E), LAMB3 (F) and LAMC2 (G).

Regulation of laminin-332 expression by miR-218

To investigate the effect of miR-218 transfection on the expression levels of laminin-332 (LAMA3, LAMB3 and LAMC2), we performed qRT-PCR and Western blotting using FaDu and SAS. The mRNA expression levels of LAMB3 and LAMC2 were significantly decreased in miR-218 transfectants compared with miR-control transfectants (Figure 3A). Although restoration of miR-218 significantly suppressed LAMA3 expression in FaDu, no significant downregulation of LAMA3 was observed in SAS (Figure 3A). Western blotting demonstrated similar effect of miR-218 on protein expression levels of laminins-332 (Figure 3B).
Figure 3

Laminin-332 expression was suppressed by miR-218 transfection at both the mRNA and protein levels in HNSCC cell lines

(A) mRNA expression of LAMA3, LAMB3 and LAMC2 as revealed by qRT-PCR 48 h after transfection with 10 nM of miR-218. GUSB was used as internal controls. *p< 0.05. (B) Protein expression of LAMA3, LAMB3 and LAMC2 as revealed by western blot analysis 48 h after transfection with 10 nM of miR-218. GAPDH was used as loading controls. The expression ratio of LAMA3, LAMB3 and LAMC2 were evaluated using ImageJ software.

Laminin-332 expression was suppressed by miR-218 transfection at both the mRNA and protein levels in HNSCC cell lines

(A) mRNA expression of LAMA3, LAMB3 and LAMC2 as revealed by qRT-PCR 48 h after transfection with 10 nM of miR-218. GUSB was used as internal controls. *p< 0.05. (B) Protein expression of LAMA3, LAMB3 and LAMC2 as revealed by western blot analysis 48 h after transfection with 10 nM of miR-218. GAPDH was used as loading controls. The expression ratio of LAMA3, LAMB3 and LAMC2 were evaluated using ImageJ software. The target prediction databases indicated one putative target site in the 3' untranslated region (3'UTR) of LAMB3 (Figure 4A). To determine whether LAMB3 mRNA had a functional target site, we performed luciferase reporter assay. The luminescence intensity was significantly reduced by transfection of miR-218 compared with miR-control transfection (Figure 4B).
Figure 4

miR-218 directly regulates LAMB3 by luciferase reporter assay

(A)Putative miR-218 binding site in the 3'UTR of LAMB3 mRNA was identified with the TargetScan database. (B) Luciferase reporter assay was performed using the vector encoding partial sequences of 3'UTR which contained the putative miR-218 target site. The vector (10 ng) and miR-218 or miR-control (10 nM) were cotransfected into FaDu and SAS cell lines. Renila luciferase activity was measured after 24h transfection. The results were normalized by firefly luciferase values. *p < 0.05.

miR-218 directly regulates LAMB3 by luciferase reporter assay

(A)Putative miR-218 binding site in the 3'UTR of LAMB3 mRNA was identified with the TargetScan database. (B) Luciferase reporter assay was performed using the vector encoding partial sequences of 3'UTR which contained the putative miR-218 target site. The vector (10 ng) and miR-218 or miR-control (10 nM) were cotransfected into FaDu and SAS cell lines. Renila luciferase activity was measured after 24h transfection. The results were normalized by firefly luciferase values. *p < 0.05.

Effect of LAMB3 silencing on cell proliferation, migration and invasion activities of HNSCC cell lines

A loss-of-function assay using siRNA analysis was performed to examine the function of LAMB3 in cancer cells. The expression levels of LAMB3 mRNA and LAMB3 protein were repressed by si-LAMB3 in FaDu and SAS (Figure 5A and 5B).
Figure 5

LAMB3 expression was suppressed by si-LAMB3 transfection at both the mRNA and protein levels in HNSCC cell lines

(A) mRNA expression of LAMB3 as revealed by real-time qRT-PCR 48 h after transfection with 10 nM of si-LAMB3. *p < 0.0083. (B) Protein expression of LAMB3 as revealed by western blot analysis 48 h after transfection with 10 nM of si-LAMB3. GAPDH was used as loading controls. The expression ratio of LAMB3 was evaluated using ImageJ software.

LAMB3 expression was suppressed by si-LAMB3 transfection at both the mRNA and protein levels in HNSCC cell lines

(A) mRNA expression of LAMB3 as revealed by real-time qRT-PCR 48 h after transfection with 10 nM of si-LAMB3. *p < 0.0083. (B) Protein expression of LAMB3 as revealed by western blot analysis 48 h after transfection with 10 nM of si-LAMB3. GAPDH was used as loading controls. The expression ratio of LAMB3 was evaluated using ImageJ software. The XTT assay revealed that cell proliferation was significantly repressed in FaDu and SAS 72 h after si-LAMB3 transfection compared with mock and si-control (Figure 6A). Migration assays revealed that the number of migrated cells was significantly smaller in si-LAMB3 transfectants compared with mock and si-controls (Figure 6B), and Matrigel invasion assays also showed that the number of invaded cells was significantly smaller in si-LAMB3 transfectants in FaDu and SAS (Figure 6C).
Figure 6

Effects of LAMB3 knockdown by si-LAMB3 transfection on HNSCC cell lines, FaDu and SAS

(A) Cell proliferation activities as revealed by XTT assay in HNSCC cell lines, FaDu and SAS. *p < 0.0083 (B) Cell migration activities (migration assay) of HNSCC cells. *p < 0.0083 (C) Cell invasion activities (Matrigel invasion assay) of HNSCC cells. *p < 0.0083

Effects of LAMB3 knockdown by si-LAMB3 transfection on HNSCC cell lines, FaDu and SAS

(A) Cell proliferation activities as revealed by XTT assay in HNSCC cell lines, FaDu and SAS. *p < 0.0083 (B) Cell migration activities (migration assay) of HNSCC cells. *p < 0.0083 (C) Cell invasion activities (Matrigel invasion assay) of HNSCC cells. *p < 0.0083

Effect of LAMB3 silencing on molecular pathways

To investigate molecular pathways regulated by LAMB3, a genome-wide gene expression analysis was performed comparing the expression of si-LAMB3 transfectants with that of si-control transfectants in FaDu. A total of 852 genes were downregulated and 381 genes were upregulated in si-LAMB3 transfectants (Supplementary Table 3 and 4). We assigned the downregulated genes to KEGG annotations using singular enrichment analysis of GeneCodis [27, 28] and significantly enriched annotations were listed in table 5. We focused on the Focal adhesion pathway and the genes categorized to this pathway were listed in Table 6 and highlighted in KEGG map (Figure 7). Among them, several integrin signaling downstream molecules (JUN, RAC1 and PXN) were included.
Table 5

Pathway analysis of downregulated genes in si-LAMB3 transfected FaDu

Nunber of genesP valueAnnotations
206.64E-04Pathways in cancer
194.90E-06Focal adhesion
169.86E-09Systemic lupus erythematosus
143.97E-04Protein processing in endoplasmic reticulum
131.23E-04Lysosome
138.46E-04Purine metabolism
132.96E-03Chemokine signaling pathway
137.78E-03Regulation of actin cytoskeleton
117.38E-04Oocyte meiosis
91.41E-03ECM-receptor interaction
91.41E-03Small cell lung cancer
84.27E-04Mineral absorption
82.02E-03Pancreatic cancer
89.76E-03Pyrimidine metabolism
78.91E-03Renal cell carcinoma
64.60E-03Glutathione metabolism
49.93E-03Biosynthesis of unsaturated fatty acids
Table 6

Downregulated genes in si-LAMB3 transfectants in the focal adhesion pathway

Gene symbolGene nameLog2 ratio
LAMB3laminin, beta 3−2.50
VASPvasodilator-stimulated phosphoprotein−2.23
LAMC2laminin, gamma 2−1.80
JUNjun proto-oncogene−1.56
ITGAVintegrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51)−1.17
IGF1Rinsulin-like growth factor 1 receptor−1.08
ITGB1integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12)−0.96
RAF1v-raf-1 murine leukemia viral oncogene homolog 1−0.91
VEGFCvascular endothelial growth factor C−0.90
LAMC1laminin, gamma 1 (formerly LAMB2)−0.84
LAMA3laminin, alpha 3−0.82
FLNBfilamin B, beta−0.66
ITGA3integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor)−0.65
PXNpaxillin−0.62
VCLvinculin−0.61
METmet proto-oncogene (hepatocyte growth factor receptor)−0.58
RAC1ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1)−0.58
AKT2v-akt murine thymoma viral oncogene homolog 2−0.55
PPP1CCprotein phosphatase 1, catalytic subunit, gamma isozyme−0.50
Figure 7

Putative LAMB3 regulated genes in “focal adhesion pathway”

Putative LAMB3 regulated genes in “focal adhesion pathway” from Kyoto Encyclopedia of Genes and Genomes (KEGG). The putative LAMB3 regulated genes (highlighted in red) as defined by KEGG pathway and determined through GENECODIS analysis.

Putative LAMB3 regulated genes in “focal adhesion pathway”

Putative LAMB3 regulated genes in “focal adhesion pathway” from Kyoto Encyclopedia of Genes and Genomes (KEGG). The putative LAMB3 regulated genes (highlighted in red) as defined by KEGG pathway and determined through GENECODIS analysis.

DISCUSSION

Despite of the considerable advances in cancer treatments, the overall survival rate of HNSCC patients has not markedly improved in recent decades [2]. The poor survival is caused by locoregional recurrence, distant metastasis and second primary cancers. Many studies have indicated that cell adhesion and extra-cellular matrix proteins contribute to the cancer cell abilities for invasion, migration and metastasis [29]. However, the molecular mechanisms of invasion and metastasis of HNSCC have not yet been fully elucidated at present. Growing body of evidence indicated that miRNAs contribute to cancer initiation, development and metastasis [6, 30]. Based on this point, we have sequentially identified tumor suppressive miRNAs and miRNA-mediated molecular targets contributing to cancer cell invasion and metastasis, such as miR-1 regulates TAGLN2, miR-145-FSCN1/LASP1, miR-133a-MSN and miR-138-VIM [9, 20, 31-33]. It is known that these genes are categorized to actin-cytoskeleton or focal adhesion pathways, and deeply affect cell migration and invasion. Therefore, identification of miRNA-regulated focal adhesion pathway is important for further developments in human cancer research. Thus, we have been investigating how tumor suppressive miRNA regulates cancer pathways that are contributing to cancer cell migration and invasion. Our previous study of HNSCC miRNA signatures showed that miR-218 was downregulated in cancer tissues, suggesting that it would be a candidate of tumor suppressive miRNA [7, 8]. In this study, we validated the downregulation of miR-218 in HNSCC clinical specimens. In human genome, two miR-218 precursor genes, miR-218-1 and miR-218-2, have identical sequences in the mature miRNA and mapped to human chromosome 4p15.31 and 6q35.1, respectively. Interestingly, the genomic regions of miR-218-1 and miR-218-2 are located in the introns of SLIT2 and SLIT3 genes respectively. The downregulation of miR-218 in cancer cell was caused by promoter hypermethylation of SLIT2 and SLIT3 genes [22]. Silencing of miR-218 by DNA hypermethylation was also reported in oral SCC using a function-based screening approach [21]. Little is known about epigenetic control of miRNAs expression in cancer cells. It will be important problems to elucidate it in cancer research fields in future. Importantly, we found significant inhibition of cell migration and invasion in HNSCC cell lines (FaDu and SAS) by restoration of miR-218. These data suggested that miR-218 had a tumor suppressive function especially contributing to cell migration and invasion in HNSCC. Tumor suppressive function of miR-218 was also reported in several types of cancer targeting several oncogenic genes, such as RICTOR (oral cancer), survivin and ROBO1 (nasopharyngeal cancer), and ROBO1 (gastric cancer) [21, 22, 26]. A single miRNA is capable of targeting a number of genes to regulate biological processes globally. The elucidation of novel cancer pathways regulated by tumor suppressive miR-218 is important for our understanding of HNSCC invasion and metastasis. Based on this view, we searched miR-218-mediated molecular pathways in HNSCC cells by combination of genome-wide gene expression data and in silico analysis. In this study, we focused on focal adhesion pathway and laminin-332 as a candidate target of miR-218 in HNSCC cells. We chose laminin-332 for the following reasons. First, all components of laminin-332 (LAMA3, LAMB3 and LAMC2) are listed on the candidate target genes in the focal adhesion pathway. Second, LAMB3 have a putative miR-218 target site in their 3'untranslated regions. Our data demonstrated that mRNA expression levels of three components of laminin-332 (LAMA3, LAMB3 and LAMC2) were reduced by miR-218 transfection in HNSCC cells. Downregulation of LAMB3 by miR-218 was also reported in cervical carcinoma cells by conducting qRT-PCR and western blot analyses [34]. In this study, we firstly demonstrated that LAMB3 possessed an actual miR-218 biding site by the luciferase reporter assay. These results showed that miR-218 specifically targeted LAMB3 in HNSCC cells. The functional significance of LAMB3 in HNSCC was also investigated using a loss-of-function assay. Our data clearly showed that LAMB3 functioned as an oncogene and strongly contributed to cancer cell migration and invasion. Laminin-332, a heterotrimer composed of three chains (LAMA3, LAMB3 and LAMC2), is an adhesion substrate for epithelial cells, and regulates epithelial cell migration during epithelial regeneration and repair processes [35, 36]. Several immunohistochemical studies have shown that laminin-332 or its subunit LAMC2 is expressed in tumor cells at the invasion front or in budding tumor cells in many types of human cancers such as adenocarcinomas of colon, breast, pancreas and lung and SCC of esophagus, and melanoma [35]. Therefore, one of the chains, LAMC2 is a specific marker for invasive tumors [37]. The beta-catenin (Wnt) signaling pathway is known to induce a coordinate expression of laminin-332-LAMC2 chain and MT1-MMP in colorectal carcinomas [38]. In this study, LAMC2 was upregulated in cancer tissues and confirmed previous reports. Although there is no putative miR-218 target site in LAMC2 gene, silencing of LAMC2 mRNA expression was observed in miR-218 transfectants. Because LAMC2 was also downregulated in the expression profile of si-LAMB3 transfectants, it is assumed that the downregulation of LAMB3 somehow suppresses LAMC2 expression. The analysis of the molecular mechanism of downregulation of LAMC2 by miR-218 is needed. Furthermore, we asked why LAMB3 has an oncogenic function in HNSCC. We conducted gene expression analysis using si-LAMB3 to monitor LAMB3-controlled genes. In this study, several integrin signaling downstream molecules (JUN, RAC1 and PXN) were downregulated in the expression profile of si-LAMB3 transfectants. Many studies indicated that laminin-332 binds to several cell-surface receptors, such as integrins, epidermal growth factor receptor and syndecan-1 [39-41]. Among them, the integrins are cell surface transmembrane proteins that mediate the extracellular signals and the intracellular pathways leading to cell cycle controlling, cell migration and invasion of cancer cells [42]. Integrins are heterodimeric transmembrane receptors composed of an alpha and a beta subunit. To date, a total of 18 different alpha and 8 different beta subunits have been identified, accounting for at least 24 distinct integrin heterodimers [43]. Among those integrins, laminin-332 interacts with two major integrins receptors, alpha3beta1 and alpha6beta4, promoting the formation of focal adhesions and stable anchoring contacts [36]. In cancer cells, laminin-332-integrin alpha6beta4 interaction triggers a number of signaling cascades, promoting both cell migration and cancer survival [44]. Very interestingly, integrin beta4 gene (ITGB4) was reduced in miR-218 transfectant in our profile and ITGB4 contained putative miR-218 binding site. We confirmed that ITGB4 was reduced by miR-218 transfection by PCR methods (data not shown). These data suggested that miR-218 regulated laminin-332-integrin alpha6beta4 signal pathway in HNSCC cells. Silencing of tumor suppressive miR-218 and upregulation of its signal pathway directly contribute to cancer cell migration and invasion in HNSCC. In conclusions, our analysis data showed tumor suppressive miR-218 contributed to cancer cell migration and invasion through regulating focal adhesion pathway, especially laminin-332. Elucidation of tumor suppressive miR-218-regulated cancer pathways provides the novel therapeutic strategy to control local tumor recurrence and distant metastasis of HNSCC.

METHODS

HNSCC cell lines

Two human HNSCC cell lines were utilized: FaDu (derived from hypopharyngeal squamous cell carcinoma) and SAS (derived from a primary lesion of tongue squamous cell carcinoma). FaDu and SAS were cultured in DMEM with 10% FBS in a humidified 5% CO2 atmosphere at 37°C.

RNA isolation

Total RNA was isolated using TRIzol Reagent (Invitrogen, USA) according to the manufacturer's protocol. RNA concentrations were determined spectrophotometrically, and molecular integrity was checked by gel electrophoresis. RNA quality was confirmed using an Agilent 2100 Bioanalyzer (Agilent Technologies, USA).

Quantitative reverse-transcription-PCR (qRT-PCR)

First-strand cDNA was synthesized from 1.0 μg of total RNA using a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Gene-specific PCR products were assayed continuously using a 7900 HT Real-Time PCR System according to the manufacturer's protocol. TaqMan® probes and primers for LAMA3 (P/N: Hs00165042_m1), LAMB3 (P/N: Hs00165078_m1), LAMC2 (P/N: Hs01043711_m1) and GUSB (P/N: Hs99999908_m1) (the internal control) were obtained from Applied Biosystems (Assay-On-Demand Gene Expression Products). The expression level of miR-218 (Assay ID: 000521) was analyzed by TaqMan quantitative real-time PCR (TaqMan® MicroRNA Assay, Applied Biosystems) and normalized to RNU48 (Assay ID: 001006). The relative expression levels were analyzed using the 2−ΔΔCT method [45]. All reactions were performed in triplicate, and included negative control reactions that lacked cDNA.

Mature miRNA transfection and small interfering RNA treatment

The following RNA species were used in this study: mature miRNA, Pre-miR™ miRNA Precursor (hsa-miR-218; Applied Biosystems, USA, P/N: AM17100), negative control miRNA (Applied Biosystems, P/N: AM17111), small interfering RNA (Silencer Select, Applied Biosystems, si-LAMB3, P/N: s8075 and s8076) and negative control siRNA (Stealth™ RNAi Negative Control Medium GC Duplex, Invitrogen, P/N:12935-300). miRNAs were incubated with Opti-MEM (Invitrogen) and Lipofectamine™ RNAiMax Reagent (Invitrogen) as described previously [12]. Transfection efficiency of Pre-miR™ in cell lines was confirmed based on downregulation of TWF1 (PTK9) mRNA following transfection with miR-1 as previously reported [9, 31].

Cell proliferation, migration and invasion assays

Cells were transfected with 10 nM miRNA by reverse transfection and 3 × 103 cells were transferred to each well of a 96-well plate. After 72 h, cell proliferation was determined with the XTT assay, using the Cell Proliferation Kit II (Roche Molecular Biochemicals, Germany) as previously reported [7, 9]. A cell migration assay was performed using modified Boyden Chambers (Transwells, Corning/Costar #3422, USA) containing an uncoated Transwell polycarbonate membrane filter with 8 μm pores in 24-well tissue culture plates. Cells were transfected with 10 nM miRNA by reverse transfection and plated in 10 cm dishes at 8 × 105 cells. After 48 h, 2 × 105 cells were added to the upper chamber of each migration well and were allowed to migrate for 48 h. After gentle removal of the nonmigratory cells from the filter surface of the upper chamber, the cells that migrated to the lower side were fixed and stained with Diff-Quick (Sysmex Corporation, Japan). The number of cells migrating to the lower surface was determined microscopically by counting four areas of constant size per well. A cell invasion assay was carried out using modified Boyden chambers containing Transwell-precoated Matrigel membrane filter inserts with 8 μm pores in 24-well tissue culture plates at 2 × 105 cells per well (BD Biosciences, USA) [31]. All experiments were performed in triplicate.

Target gene search for miR-218 and pathway analysis

A genome-wide screen was performed to identify gene targets for miR-218 in FaDu and SAS cells. SurePrint G3 Human GE 8×60K Microarray (Agilent Technologies) was used for expression profiling of miR-218 transfectants in comparison with miRNA-negative control transfectants. miRNA-control transfectants that produced raw signal values of less than 1,000 were excluded before comparisons were made. miRWalk March 2011 release [http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/] and TargetScan release 6.2 [http://www.targetscan.org/] were used to identify predicted target genes and their miRNA binding site seed regions. Sequences of the predicted mature miRNAs were confirmed using miRBase release 18.0 [http://microrna.sanger.ac.uk/].

Clinical HNSCC specimens

Written consent for tissue donation for research purposes was obtained from each patient before tissue collection. The protocol was approved by the Institutional Review Board of Chiba University. Thirty-five pairs of primary tumor tissues and corresponding normal epithelial tissues were obtained from patients with HNSCC in Chiba University Hospital (Chiba, Japan) from 2007 to 2012. The normal tissue was confirmed to be free of cancer cells by pathologic examination. The specimens were immersed in RNAlater (Qiagen, USA) and stored at −20°C until RNA was extracted. The patients were classified according to 2002 Union for International Cancer Control TNM staging criteria before treatment.

Western blot analysis

Cells were harvested and lysed 48 h after transfection. Each cell lysate (50 μg of protein) was separated using Mini-PROTEAN TGX gels (Bio-Rad, USA) and transferred to PVDF membranes. Immunoblotting was performed with polynoclonal LAMA3 antibody (sc-20143; Santa Cruz, USA), polyclonal LAMB3 antibody (HPA008069; Sigma-Aldrich, USA) and monoclonal LAMC2 antibody (MAB19562; Millipore, USA). GAPDH antibody (ab8245; Abcam, UK) was used as an internal control. The membrane was washed and incubated with anti-rabbit IgG, HRP linked antibody or anti- mouse IgG, HRP linked antibody (#7074 and #7076; Cell Signaling Technology, USA). Complexes were visualized with an Immun-Star™ WesternC Chemiluminescence Kit (Bio-Rad), and the expression levels of these proteins were evaluated by ImageJ software (ver.1.44; http://rsbweb.nih.gov/ij/index.html).

Plasmid construction and dual-luciferase reporter assays

Partial sequences of the LAMB3 3' untranslated region that contains miR-218 target site (ggcatgccattgaaactaagagctctcaagtcaaggaagct gggctgggcagtatcccccgcctttagttctccactgggg aggaatcctggaccaagcacaaaaacttaacaaaagtgatgta aaaatgaaaagccaaataaaatctttggaaaagagcctggaggttc) were inserted between the XhoI and PmeI restriction sites in the 3'UTR of the hRluc gene in the psiCHECK-2 vector (Promega, USA). FaDu and SAS were then transfected with five ng vector, 10 nM mature miRNA molecules, Pre-miRNA miR-218 (Applied Biosystems), and one μL Lipofectamine 2000 (Invitrogen) in 100 μL Opti-MEM. Firefly and Renilla luciferase activities in cell lysates were determined using a dual-luciferase assay system (E1910; Promega). Normalized data were calculated as the quotient of Renilla/firefly luciferase activities.

Statistical analysis

The relationships between two groups and the numerical values obtained by qRT-PCR were analyzed using the Mann-Whitney U test or the paired t-test. The relationship among more than three variables and numerical values was analyzed using the Bonferroni adjusted Mann-Whitney U test. All analyses were performed using Expert StatView (version 4, SAS Institute Inc., USA).
  45 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  RNA regulation: a new genetics?

Authors:  John S Mattick
Journal:  Nat Rev Genet       Date:  2004-04       Impact factor: 53.242

3.  Glutathione S-transferase P1 (GSTP1) suppresses cell apoptosis and its regulation by miR-133α in head and neck squamous cell carcinoma (HNSCC).

Authors:  Muradil Mutallip; Nijiro Nohata; Toyoyuki Hanazawa; Naoko Kikkawa; Shigetoshi Horiguchi; Lisa Fujimura; Kazumori Kawakami; Takeshi Chiyomaru; Hideki Enokida; Masayuki Nakagawa; Yoshitaka Okamoto; Naohiko Seki
Journal:  Int J Mol Med       Date:  2010-12-22       Impact factor: 4.101

4.  Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells.

Authors:  I Martinez; A S Gardiner; K F Board; F A Monzon; R P Edwards; S A Khan
Journal:  Oncogene       Date:  2007-11-12       Impact factor: 9.867

5.  MicroRNA-218 is deleted and downregulated in lung squamous cell carcinoma.

Authors:  Morgan R Davidson; Jill E Larsen; Ian A Yang; Nicholas K Hayward; Belinda E Clarke; Edwina E Duhig; Linda H Passmore; Rayleen V Bowman; Kwun M Fong
Journal:  PLoS One       Date:  2010-09-03       Impact factor: 3.240

Review 6.  Tumour microenvironment: laminin 332 in squamous-cell carcinoma.

Authors:  M Peter Marinkovich
Journal:  Nat Rev Cancer       Date:  2007-05       Impact factor: 60.716

Review 7.  Defining the role of laminin-332 in carcinoma.

Authors:  Cherise M Guess; Vito Quaranta
Journal:  Matrix Biol       Date:  2009-08-15       Impact factor: 11.583

8.  The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer.

Authors:  H Yoshino; T Chiyomaru; H Enokida; K Kawakami; S Tatarano; K Nishiyama; N Nohata; N Seki; M Nakagawa
Journal:  Br J Cancer       Date:  2011-02-08       Impact factor: 7.640

9.  Tumour suppressive microRNA-874 regulates novel cancer networks in maxillary sinus squamous cell carcinoma.

Authors:  N Nohata; T Hanazawa; N Kikkawa; D Sakurai; L Fujimura; T Chiyomaru; K Kawakami; H Yoshino; H Enokida; M Nakagawa; A Katayama; Y Harabuchi; Y Okamoto; N Seki
Journal:  Br J Cancer       Date:  2011-08-16       Impact factor: 7.640

10.  Tumor suppressive microRNA-1285 regulates novel molecular targets: aberrant expression and functional significance in renal cell carcinoma.

Authors:  Hiedo Hidaka; Naohiko Seki; Hirofumi Yoshino; Takeshi Yamasaki; Yasutoshi Yamada; Nijiro Nohata; Miki Fuse; Masayuki Nakagawa; Hideki Enokida
Journal:  Oncotarget       Date:  2012-01
View more
  62 in total

1.  Dual-receptor (EGFR and c-MET) inhibition by tumor-suppressive miR-1 and miR-206 in head and neck squamous cell carcinoma.

Authors:  Keiichi Koshizuka; Toyoyuki Hanazawa; Ichiro Fukumoto; Naoko Kikkawa; Ryosuke Matsushita; Hiroko Mataki; Keiko Mizuno; Yoshitaka Okamoto; Naohiko Seki
Journal:  J Hum Genet       Date:  2016-05-12       Impact factor: 3.172

2.  Regulation of metastasis-promoting LOXL2 gene expression by antitumor microRNAs in prostate cancer.

Authors:  Mayuko Kato; Akira Kurozumi; Yusuke Goto; Ryosuke Matsushita; Atsushi Okato; Rika Nishikawa; Ichiro Fukumoto; Keiichi Koshizuka; Tomohiko Ichikawa; Naohiko Seki
Journal:  J Hum Genet       Date:  2016-06-09       Impact factor: 3.172

Review 3.  The microRNA signatures: aberrantly expressed microRNAs in head and neck squamous cell carcinoma.

Authors:  Keiichi Koshizuka; Toyoyuki Hanazawa; Ichiro Fukumoto; Naoko Kikkawa; Yoshitaka Okamoto; Naohiko Seki
Journal:  J Hum Genet       Date:  2016-08-25       Impact factor: 3.172

4.  Prognostic potential of KLOTHO and SFRP1 promoter methylation in head and neck squamous cell carcinoma.

Authors:  Abeer A Alsofyani; Rawiah A Alsiary; Alaa Samkari; Baraa T Alhaj-Hussain; Jalaluddin Azam Khan; Jaudah Al-Maghrabi; Aisha Elaimi; Mohammed H Al-Qahtani; Adel M Abuzenadah; Ashraf Dallol
Journal:  J Appl Genet       Date:  2017-08-16       Impact factor: 3.240

5.  Quantitative proteomic analysis of the miR-148a-associated mechanisms of metastasis in non-small cell lung cancer.

Authors:  Dandan Chu; Jing Li; Hechun Lin; Xiao Zhang; Hongyu Pan; Lei Liu; Tao Yu; Mingxia Yan; Ming Yao
Journal:  Oncol Lett       Date:  2018-04-26       Impact factor: 2.967

Review 6.  RANK-mediated signaling network and cancer metastasis.

Authors:  Gina Chia-Yi Chu; Leland W K Chung
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

7.  The impact of pri-miR-218 rs11134527 on the risk and prognosis of patients with esophageal squamous cell carcinoma.

Authors:  Lin Jiang; Chaofu Wang; Canlin Sun; Yumin Xu; Zhongqi Ding; Xueling Zhang; Junxing Huang; Hong Yu
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

8.  microRNA-449a functions as a tumor suppressor in neuroblastoma through inducing cell differentiation and cell cycle arrest.

Authors:  Zhenze Zhao; Xiuye Ma; Derek Sung; Monica Li; Adam Kosti; Gregory Lin; Yidong Chen; Alexander Pertsemlidis; Tzu-Hung Hsiao; Liqin Du
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

9.  MiR-34a suppresses amphiregulin and tumor metastatic potential of head and neck squamous cell carcinoma (HNSCC).

Authors:  Jiali Zhang; Yu Wang; Xinming Chen; Yi Zhou; Fangyan Jiang; Jirong Chen; Li Wang; Wen-Feng Zhang
Journal:  Oncotarget       Date:  2015-04-10

Review 10.  Smoking and microRNA dysregulation: a cancerous combination.

Authors:  Navneet Momi; Sukhwinder Kaur; Satyanarayana Rachagani; Apar K Ganti; Surinder K Batra
Journal:  Trends Mol Med       Date:  2013-11-13       Impact factor: 11.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.